UCB SA (LON:0NZT)

Market Cap	41.70B
Revenue (ttm)	5.87B +25.6%
Net Income	1.14B +455.0%
EPS	5.89 +462.0%
Shares Out	n/a
PE Ratio	36.52
Forward PE	27.58
Dividend	0.83 (0.32%)
Ex-Dividend Date	Apr 25, 2025

Volume	243,536
Average Volume	49,985
Open	259.75
Previous Close	260.30
Day's Range	250.35 - 259.10
52-Week Range	129.35 - 268.20
Beta	0.25
RSI	51.44
Earnings Date	Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1925
• Employees: 8,600
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NZT

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.

Financial numbers in EUR